サマリー

欧州の鼻腔スプレー市場は、2023年から2030年の予測期間に6.5%のCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。

市場セグメンテーション

欧州の点鼻薬市場：製品タイプ別（充血除去点鼻薬、ステロイド点鼻薬、塩水・生理食塩水点鼻薬、その他）、容器デザイン別（ポンプボトル、加圧キャニスター）、剤形別（多剤式、単位・単剤式、二剤式）、治療クラス（抗ヒスタミン、鼻ステロイド、肥満細胞阻害剤、抗コリン作用）、用途（鼻づまり、アレルギー性・非アレルギー性鼻炎、中枢神経系障害、ワクチン接種、その他）、処方・入手方法（市販・処方）、エンドユーザー（在宅医療、病院、診療所、地域医療）、国（ドイツ、U．K.,フランス、イタリア、スペイン、スイス、オランダ、ベルギー、ロシア、トルコ、その他ヨーロッパ）産業動向と2030年までの予測

欧州の鼻腔スプレー市場の成長に寄与する主な要因としては、以下のものが挙げられます：

- 鼻腔スプレーの治療用途の増加
- アレルギー疾患やCOVID-19などのパンデミックに対応した点鼻薬の需要増
市場関係者
欧州の点鼻薬市場で事業を展開している主な市場関係者は以下の通りです：

- エマージェンシー
- Cipla Inc.
- サンド・インターナショナルGmbH（ノバルティス社傘下）
- アイトゥヘルス（アイトゥバイオファーマ社の子会社）
- バイエル社
- グラクソ・スミスクライン plc.
- アサーティオ・セラピューティクス・インク
- アウレナ・ラボラトリーズ
- ジェイ・ファーマシューティカルズ
- セント・ルナトゥス
- ウルトラテック インディア リミテッド
- キャタレント社（Catalent, Inc.
- Teva Pharmaceuticals USA, Inc. (Teva Pharmaceutical Industries Ltd.の子会社)
- ファイザー株式会社（Pfizer Inc.
- ヴィアトリス・インク
- リーフォード・ヘルスケアLtd
- アイシワリヤグループ

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW 23
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 25
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 PRODUCT TYPE LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 MARKET END USER COVERAGE GRID 36
2.11 VENDOR SHARE ANALYSIS 37
2.12 SECONDARY SOURCES 38
2.13 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 42
4.1 PORTER’S FIVE FORCES MODEL 45
4.2 PESTEL ANALYSIS 46
5 INDUSTRY INSIGHTS: EUROPE NASAL SPRAY MARKET 47
5.1 INDUSTRY INSIGHTS 47
6 REGULATIONS: EUROPE NASAL SPRAY MARKET 48
6.1 REGULATORY SCENARIO IN EUROPE 48
7 MARKET OVERVIEW 49
7.1 DRIVERS 51
7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES 51
7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA 51
7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 52
7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 53
7.2 RESTRAINTS 54
7.2.1 PRODUCT RECALLS 54
7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS 55
7.3 OPPORTUNITIES 56
7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY 56
7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 56
7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS 57
7.4 CHALLENGES 57
7.4.1 REGULATORY HURDLES 57
7.4.2 ADDICTION TO NASAL SPRAY 58
8 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE 59
8.1 OVERVIEW 60
8.2 DECONGESTION NASAL SPRAY 63
8.3 STEROID NASAL SPRAY 64
8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY 65
8.5 OTHERS 66
9 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN 67
9.1 OVERVIEW 68
9.2 PUMP BOTTLES 71
9.3 PRESSURIZED CANISTERS 72
10 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM 73
10.1 OVERVIEW 74
10.2 MULTI DOSE 77
10.3 UNIT/SINGLE DOSE 78
10.4 BI DOSE 79
11 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 81
11.1 OVERVIEW 82
11.2 ANTIHISTAMINE 85
11.3 NASAL STEROIDS 86
11.4 MAST CELL INHIBITOR 87
11.5 ANTICHOLINERGIC 88
12 EUROPE NASAL SPRAY MARKET, BY APPLICATION 89
12.1 OVERVIEW 90
12.2 NASAL CONGESTION 93
12.3 ALLERGIC AND NON-ALLERGIC RHINITIS 94
12.4 CENTRAL NERVOUS SYSTEM DISORDERS 95
12.5 VACCINATION 96
12.6 OTHERS 97
13 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY 98
13.1 OVERVIEW 99
13.2 PRESCRIBED 102
13.3 OVER THE COUNTER 103
14 EUROPE NASAL SPRAY MARKET, BY END USER 105
14.1 OVERVIEW 106
14.2 HOME CARE SETTINGS 109
14.3 HOSPITALS 110
14.4 CLINICS 111
14.5 COMMUNITY HEALTH CARE 112
15 EUROPE NASAL SPRAY MARKET, BY REGION 113
15.1 EUROPE 114
15.1.1 GERMANY 122
15.1.2 U.K. 124
15.1.3 FRANCE 126
15.1.4 ITALY 128
15.1.5 SPAIN 130
15.1.6 SWITZERLAND 132
15.1.7 NETHERLANDS 134
15.1.8 BELGIUM 136
15.1.9 RUSSIA 138
15.1.10 TURKEY 140
15.1.11 REST OF EUROPE 142
16 EUROPE NASAL SPRAY MARKET, COMPANY LANDSCAPE 143
16.1 COMPANY SHARE ANALYSIS: EUROPE 143
17 SWOT ANALYSIS 144
18 COMPANY PROFILE 145
18.1 GLAXOSMITHKLINE PLC. 145
18.1.1 COMPANY SNAPSHOT 145
18.1.2 REVENUE ANALYSIS 145
18.1.3 COMPANY SHARE ANALYSIS 146
18.1.4 PRODUCT PORTFOLIO 146
18.1.5 RECENT DEVELOPMENTS 146
18.2 PFIZER INC. 148
18.2.1 COMPANY SNAPSHOT 148
18.2.2 REVENUE ANALYSIS 148
18.2.3 COMPANY SHARE ANALYSIS 149
18.2.4 PRODUCT PORTFOLIO 149
18.2.5 RECENT DEVELOPMENTS 149
18.3 EMERGENT 151
18.3.1 COMPANY SNAPSHOT 151
18.3.2 REVENUE ANALYSIS 151
18.3.3 COMPANY SHARE ANALYSIS 152
18.3.4 PRODUCT PORTFOLIO 152
18.3.5 RECENT DEVELOPMENT 152
18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS) 153
18.4.1 COMPANY SNAPSHOT 153
18.4.2 REVENUE ANALYSIS 153
18.4.3 COMPANY SHARE ANALYSIS 154
18.4.4 PRODUCT PORTFOLIO 154
18.4.5 RECENT DEVELOPMENT 154
18.5 CATALENT, INC. 155
18.5.1 COMPANY SNAPSHOT 155
18.5.2 REVENUE ANALYSIS 155
18.5.3 COMPANY SHARE ANALYSIS 156
18.5.4 PRODUCT PORTFOLIO 156
18.5.5 RECENT DEVELOPMENTS 156
18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.) 158
18.6.1 COMPANY SNAPSHOT 158
18.6.2 REVENUE ANALYSIS 158
18.6.3 PRODUCT PORTFOLIO 159
18.6.4 RECENT DEVELOPMENTS 159
18.7 AISHWARYA GROUP 160
18.7.1 COMPANY SNAPSHOT 160
18.7.2 PRODUCT PORTFOLIO 160
18.7.3 RECENT DEVELOPMENTS 160
18.8 ASSERTIO THERAPEUTICS, INC. 161
18.8.1 COMPANY SNAPSHOT 161
18.8.2 REVENUE ANALYSIS 161
18.8.3 PRODUCT PORTFOLIO 162
18.8.4 RECENT DEVELOPMENT 162
18.9 AURENA LABORATORIES. 163
18.9.1 COMPANY SNAPSHOT 163
18.9.2 PRODUCT PORTFOLIO 163
18.9.3 RECENT DEVELOPMENTS 163
18.10 BAYER AG 165
18.10.1 COMPANY SNAPSHOT 165
18.10.2 REVENUE ANALYSIS 165
18.10.3 COMPANY SHARE ANALYSIS 166
18.10.4 PRODUCT PORTFOLIO 166
18.10.5 RECENT DEVELOPMENTS 166
18.11 CIPLA INC. 168
18.11.1 COMPANY SNAPSHOT 168
18.11.2 REVENUE ANALYSIS 168
18.11.3 PRODUCT PORTFOLIO 169
18.11.4 RECENT DEVELOPMENT 169
18.12 J PHARMACEUTICALS. 170
18.12.1 COMPANY SNAPSHOT 170
18.12.2 PRODUCT PORTFOLIO 170
18.12.3 RECENT DEVELOPMENTS 170
18.13 LEEFORD HEALTHCARE LTD 171
18.13.1 COMPANY SNAPSHOT 171
18.13.2 PRODUCT PORTFOLIO 171
18.13.3 RECENT DEVELOPMENTS 171
18.14 ST. RENATUS. 172
18.14.1 COMPANY SNAPSHOT 172
18.14.2 PRODUCT PORTFOLIO 172
18.14.3 RECENT DEVELOPMENTS 172
18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD) 173
18.15.1 COMPANY SNAPSHOT 173
18.15.2 REVENUE ANALYSIS 173
18.15.3 PRODUCT PORTFOLIO 174
18.15.4 RECENT DEVELOPMENTS 174
18.16 ULTRATECH INDIA LIMITED 175
18.16.1 COMPANY SNAPSHOT 175
18.16.2 PRODUCT PORTFOLIO 175
18.16.3 RECENT DEVELOPMENTS 175
18.17 VIATRIS INC. 176
18.17.1 COMPANY SNAPSHOT 176
18.17.2 REVENUE ANALYSIS 176
18.17.3 COMPANY SHARE ANALYSIS 177
18.17.4 PRODUCT PORTFOLIO 177
18.17.5 RECENT DEVELOPMENT 177
19 QUESTIONNAIRE 178
20 RELATED REPORTS 182

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 56
TABLE 2 EUROPE DECONGESTION NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 58
TABLE 3 EUROPE STEROID NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 59
TABLE 4 EUROPE SALT WATER SOLUTION/SALINE NASAL SPRAY IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 5 EUROPE OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 6 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 64
TABLE 7 EUROPE PUMP BOTTLES IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 65
TABLE 8 EUROPE PRESSURIZED CANISTERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 9 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 70
TABLE 10 EUROPE MULTI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 11 EUROPE UNIT/SINGLE DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 12 EUROPE BI DOSE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 13 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 78
TABLE 14 EUROPE ANTIHISTAMINE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 15 EUROPE NASAL STEROIDS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 16 EUROPE MAST CELL INHIBITOR IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 17 EUROPE ANTICHOLINERGIC IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 18 EUROPE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 86
TABLE 19 EUROPE NASAL CONGESTION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 20 EUROPE ALLERGIC AND NON-ALLERGIC RHINITIS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 21 EUROPE CENTRAL NERVOUS SYSTEM DISORDERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 22 EUROPE VACCINATION IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 23 EUROPE OTHERS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 24 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 95
TABLE 25 EUROPE PRESCRIBED IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 26 EUROPE OVER THE COUNTER IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 27 EUROPE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 102
TABLE 28 EUROPE HOME CARE SETTINGS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 29 EUROPE HOSPITALS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 30 EUROPE CLINICS IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 31 EUROPE COMMUNITY HEALTH CARE IN NASAL SPRAY MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 32 EUROPE NASAL SPRAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 113
TABLE 33 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 113
TABLE 34 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 113
TABLE 35 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 114
TABLE 36 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 114
TABLE 37 EUROPE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 114
TABLE 38 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 114
TABLE 39 EUROPE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 115
TABLE 40 GERMANY NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 116
TABLE 41 GERMANY NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 116
TABLE 42 GERMANY NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 116
TABLE 43 GERMANY NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 116
TABLE 44 GERMANY NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 117
TABLE 45 GERMANY NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 117
TABLE 46 GERMANY NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 117
TABLE 47 U.K. NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 118
TABLE 48 U.K. NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 118
TABLE 49 U.K. NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 118
TABLE 50 U.K. NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 118
TABLE 51 U.K. NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 119
TABLE 52 U.K. NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 119
TABLE 53 U.K. NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 119
TABLE 54 FRANCE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 120
TABLE 55 FRANCE NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 120
TABLE 56 FRANCE NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 120
TABLE 57 FRANCE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 120
TABLE 58 FRANCE NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 121
TABLE 59 FRANCE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 121
TABLE 60 FRANCE NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 121
TABLE 61 ITALY NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 122
TABLE 62 ITALY NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 122
TABLE 63 ITALY NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 122
TABLE 64 ITALY NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 122
TABLE 65 ITALY NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 123
TABLE 66 ITALY NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 123
TABLE 67 ITALY NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 123
TABLE 68 SPAIN NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124
TABLE 69 SPAIN NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 124
TABLE 70 SPAIN NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 124
TABLE 71 SPAIN NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 124
TABLE 72 SPAIN NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 125
TABLE 73 SPAIN NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 125
TABLE 74 SPAIN NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 125
TABLE 75 SWITZERLAND NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 126
TABLE 76 SWITZERLAND NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 126
TABLE 77 SWITZERLAND NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 126
TABLE 78 SWITZERLAND NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 126
TABLE 79 SWITZERLAND NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 127
TABLE 80 SWITZERLAND NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 127
TABLE 81 SWITZERLAND NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 127
TABLE 82 NETHERLANDS NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 83 NETHERLANDS NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 128
TABLE 84 NETHERLANDS NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 128
TABLE 85 NETHERLANDS NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 128
TABLE 86 NETHERLANDS NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 129
TABLE 87 NETHERLANDS NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 129
TABLE 88 NETHERLANDS NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 129
TABLE 89 BELGIUM NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 130
TABLE 90 BELGIUM NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 130
TABLE 91 BELGIUM NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 130
TABLE 92 BELGIUM NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 130
TABLE 93 BELGIUM NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 131
TABLE 94 BELGIUM NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 131
TABLE 95 BELGIUM NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 131
TABLE 96 RUSSIA NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 132
TABLE 97 RUSSIA NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 132
TABLE 98 RUSSIA NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 132
TABLE 99 RUSSIA NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 132
TABLE 100 RUSSIA NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 133
TABLE 101 RUSSIA NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 133
TABLE 102 RUSSIA NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 133
TABLE 103 TURKEY NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 134
TABLE 104 TURKEY NASAL SPRAY MARKET, BY CONTAINER DESIGN, 2021-2030 (USD MILLION) 134
TABLE 105 TURKEY NASAL SPRAY MARKET, BY DOSAGE FORM, 2021-2030 (USD MILLION) 134
TABLE 106 TURKEY NASAL SPRAY MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION) 134
TABLE 107 TURKEY NASAL SPRAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 135
TABLE 108 TURKEY NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY, 2021-2030 (USD MILLION) 135
TABLE 109 TURKEY NASAL SPRAY MARKET, BY END USER, 2021-2030 (USD MILLION) 135
TABLE 110 REST OF EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 136